Allogeneic stem cell transplantation (ASCT) has improved leukemia-free survival (LFS) in many but not all patients with acute leukemia. This is an eight-year followup to our previous study showing a survival advantage to patients with an increased cd T cells following ASCT. cd T cell levels were collected prospectively in 153 patients (acute lymphoblastic leukemia (ALL) n ¼ 77; acute myelogenous leukemia (AML) n ¼ 76) undergoing partially mismatched related donor ASCT. Median age was 22 years (1-59), and 62% of the patients were in relapse at transplant. Patient-donor human leukocyte antigen (HLA) disparity of three antigens was 37% in the graft-versushost disease (GvHD) and 29% in the rejection directions. All patients received a partially T cell-depleted graft using T10B9 (n ¼ 46) or OKT3 (n ¼ 107). Five years LFS and overall survival (OS) of patients with increased cd compared to those with normal/decreased numbers were 54.4 vs 19.1%; Po0.0003, and 70.8 vs 19.6% Po0.0001, respectively, with no difference in GvHD (P ¼ 0.96). In a Cox multivariate analysis, normal/decreased cd (hazard ratio (HR) 4.26, P ¼ 0.0002) and sex mismatch (HR 1.45 P ¼ 0.049) were associated with inferior LFS. In conclusion, cd T cells may facilitate a graft-versus-leukemia (GvL) effect, without causing GvHD. Further evaluations of this effect may lead to specific immunotherapy for patients with refractory leukemia.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) has improved disease-free survival in patients with refractory acute leukemia, or those at a high risk of relapse. Over the past several years, it became apparent that the donor graft, in addition to its role in replacement of the ablated hematopoietic system, elicits an immunotherapeutic benefit (graft-versus-leukemia effect (GvL)). The role of T cells as mediators of GvL was recognized when T cell depletion of hematopoietic grafts was found to be associated with an increased risk of relapsed disease, especially in patients with chronic myeloid leukemia. [1] [2] [3] [4] [5] Subsequently, donor leukocyte infusion (DLI) therapy (containing primarily T cells) was found to induce a long-term remission in early relapse CML patients. [6] [7] [8] [9] [10] [11] Less frequent response to DLI has been seen in patients with advanced stage CML or those with acute leukemia. 6, 7, 10 The extent of response to DLI may depend on the type of leukemia, its replication rate, whether it expresses leukemia-specific target antigens and on recognition and killing of minor and/or major mismatched histocompatibility antigens. [12] [13] [14] [15] Unfortunately, GvL is often linked with graft-versus-host disease (GvHD), as demonstrated by a number of studies showing a decreased relapse rate in patients who developed acute or chronic GvHD. 1, 16 Various T cell subset selection methods have been applied to DLI in an attempt to separate the GvL effect from GvHD. Despite these attempts, the risk of GvHD remains an obstacle to successful DLI therapy, prompting a substantial amount of investigative work that has focused on the search for allogeneic cellular immunotherapy that would minimize the risk of GvHD while providing effective protection against or therapy for post HSCT leukemic relapse. 8, 12, [17] [18] [19] [20] [21] [22] Gamma/delta (gd) T cells may provide an ideal source of T cell immunotherapy for leukemia, as they exhibit biologic characteristics consistent with innate immune recognition, thereby allowing them to respond to malignancy without recognition of alloantigens that could result in GvHD.
Unlike ab T cells, which recognize specific processed peptide antigens presented on major histocompatibility complex (MHC) molecules by antigen-presenting cells, gd T cells directly recognize and respond to a variety of MHClike stress-induced self antigens expressed by malignant cells. [23] [24] [25] [26] [27] Thus, gd T cells can recognize malignant cells through less specific mechanisms that require no prior antigen exposure or priming, a function that is shared by other innate immune cells such as macrophages and natural killer (NK) cells. 28 Preliminary observations from our group have shown that patients who develop increased numbers of donorderived circulating gd T cells following haploidentical or partially mismatched HSCT experienced a significant leukemia-free survival (LFS) and overall survival (OS) advantage. 29 This report is up to 8 years, follow-up of these and additional patients, and a comparative analysis of concomitantly treated patients who received the same transplant protocols in our institution and recovered with normal/low levels of gd T cells.
Methods

Patient selection
Data were collected prospectively on all consecutive acute leukemia patients who received partially mismatched related donor (PMRD) HSCT between February 1993 and December 1999 at the Division of Transplantation Medicine of the South Carolina Cancer Center. All patients and donors provided written informed consent, and all research was conducted under institutional review boardapproved protocols.
Patients were excluded if they had a secondary malignancy (including secondary acute myelogenous leukemia (AML)), were beyond first transplant or received a nontotal-body-irradiation containing regimen. To reduce selection bias, only patients surviving beyond 59 days post transplantation, were included in the analysis. In addition, patients were evaluable for increased gd T cells only after day þ 59 owing to incomplete T-cell recovery before that time.
Laboratory studies Blasts were extensively characterized by morphologic examination, flow cytometry and cytogenetics. Whole peripheral blood was collected from donor and recipient before HSCT and from the recipient on days þ 60, þ 100, þ 180, þ 270, þ 365 post transplant and annually thereafter. Aliquots of 100 ml were labeled with flourochromeconjugated antibodies specific for lymphocytes and T cell subsets (CD3, CD4, CD8, CD19, CD16/56, CD45, TCR-gd and Vd1-Vd3), and prepared using a commercially available erythrocyte-lysis procedure. Acquisition and analysis were performed using a FACS Calibur flow cytometer and CellQuest Pro acquisition and analysis software (BD Biosciences, San Jose, CA, USA). Cell subpopulations in the lymphocyte CD45/side scatter gate were quantitated and expressed as a percentage of the total lymphocyte population. The gd T cells were calculated as a percentage of the total lysed whole blood lymphocyte count (CD45/SSC gating followed by determination of gd T cells as a percentage of lymphocytes) and a BeckmanCoulter ACT-2 hematology analyzer for absolute lymphocyte count (percent gd lymphocytes Â absolute lymphocyte count).
Patients were included in the increased gd group if they had a total of 1.75 Â 10 5 gd T cells/ml of whole blood at two consecutive regularly scheduled lymphocyte phenotyping measurements within the first year post bone marrow transplantation (post BMT) (days þ 60, þ 100, þ 180, þ 270 and þ 365). The definition of increased gd T cells was based on data from 498% of 201 healthy allogeneic donors from our center, and on the calculation of 5% (gd T cells) of total lymphocyte 4 Â 10 6 /ml.
Conditioning regimens and GvHD prophylaxis
Patients' conditioning therapy and GvHD prophylaxis had been previously described.
30,31 Table 1 shows the characteristics of patients recovering with high vs normal/low levels of gd T cells. The marrow was depleted of T cells using the monoclonal antibodies T10B9 (1993-1994) or OKT3 (1995-1999) as described previously. [30] [31] [32] [33] Acute and chronic GvHD were diagnosed and staged based on standard criteria, and treated with combination immunosuppressive therapy.
Statistical analysis
Altogether, we evaluated 14 potential risk factors for eventfree survival and overall survival including age (as continuous, stratified by median and by decade), gender, race (Caucasian vs other), disease (acute lymphoblastic leukemia (ALL) vs AML), disease status (remission vs relapse), pre-transplant cytomegalovirus (CMV) serology of recipient (positive vs negative), CMV serology of donor (positive vs negative), donor relationship (sibling vs other) and age (o28 vs X28 years), sex mismatch, T cell-depleting agent (OKT3 vs other), human leukocyte antigen (HLA) mismatch in the graft-versus-host direction (o3 vs 3) and in the rejection direction (o3 vs 3) and gd status (high vs normal/low). Kaplan-Meier curves were conducted for time to OS and LFS for gd T cell status (high and normal/ low) and primary disease (AML and ALL), and compared by log-rank test. P-values less than 0.05 were considered to indicate statistical significance. The Cox proportional hazard model was used to estimate the relative risk of individual risk factors, with confidence interval (CI) of 95%. The effect of gd status (elevated or not) and potential factors were analyzed using stepwise Cox proportionalhazard model, with a value of P ¼ 0.05 necessary to enter into the model. Cumulative incidence was calculated as per Gray 34 and the IBMTR/ABMTR Statisticians Manual. All analyses were performed with SAS software (version 8.1).
Results
Patients
From 1993 to 1999, of 201 patients with acute leukemia who underwent PMRD HSCT, 153 (ALL n ¼ 77; AML n ¼ 76) survived to day þ 59 and were included in the analysis. Of these, 18 patients (ALL n ¼ 14, AML n ¼ 4) recovered with an increased gd T cell number. The remaining 135 patients recovered with a normal or decreased level of gd T cells. Median day to development of elevated gd T cells was 140 days, whereas median day to survival in the low gd group was 193 days. Median followup of the survivors was 1771 days.
Frequencies of patient, donor and transplant characteristics are detailed in Table 1 . Among 153 acute leukemia patients, median age was 22 years (1-59) and most patients (62%) were in relapse at transplant. Major HLA disparity was A, B and DR loci mismatched in 37% of patients (graft-versus-host direction) and 29% of donors (rejection direction). Donors' median age was 27 (4-67) years and 46% donor-recipient pairs were sex mismatched. All patients received partially T cell-depleted grafts, prepared with T10B9 anti-ab (n ¼ 46) or OKT3 pan-T cell (n ¼ 107) monoclonal antibody. Patients who recovered with increased number of circulating gd T cells were, in general, younger, more likely to be male and more often carried the diagnosis of ALL. Also, their donors were younger. No other characteristic differed between patients with increased vs normal/low gd T cell count. It is of interest that although patients who recovered with an increased gd T cell count did not receive a substantial higher dose of T cell dose in their grafts (median 52 500 vs 48 000 T cells/kg), they were more likely to receive T10B9 (anti-ab antibody)-depleted grafts than OKT3 (pan T cell antibody)-depleted grafts (15 vs 10%).
Leukemia-free-survival and overall survival Patients with ALL and AML were analyzed together as no significant differences were seen between disease outcomes (data not shown). Patients who recovered with an increased number of gd had a better LFS compared to those who recovered with normal/low numbers, resulting in a 5-year LFS of 54.4 vs 19.1%, P ¼ 0.0003 (Figure 1a) . Similarly, Kaplan-Meier analysis of OS showed that patients recovering with an increased gd T cell count had an Table 1 Frequencies of patient, donor and transplant characteristics comparing patients with high vs normal/low gd T cells following bone marrow transplantation
Variable
Increased gd, improved 5-year survival over those who recovered with normal or lower numbers (5-year OS: 70.8 vs 19.6%, Po0.0001 by log-rank test, Figure 1b) . To prevent the possible selection bias of patients who survived longer, another analysis limited to patients who survived beyond day þ 140 (the median day of increased gd T cell recovery) showed the same survival advantage in increased gd T cell patients (5-year LFS and OS of increased compared to low/ normal gd T cell was 57.7 vs 30.9%, P ¼ 0.0082 and 70.8 vs 27.9%, P ¼ 0.0005, respectively).
In a Cox univariate analysis of LFS, two factors were found to have a statistically significant association with a negative outcome: normal/low gd T cells (P ¼ 0.0007) and donor age X28 (P ¼ 0.018). In the Cox multivariate regression analysis, normal/low level of gd T cells (P ¼ 0.0002) was still significant, whereas donor age was not and mismatched donor sex emerged with a borderline significance (P ¼ 0.049). Overall, patients with a normal/low gd T cell count had 4.3 (95% CI 1.9-9.7) times greater risk of unfavorable LFS compared to those who had increased gd after accounting for the effect of the mismatched donor sex (Table 2) . Similarly for OS, in a univariate analysis, low/normal gd (P ¼ 0.0002), donor age X28 (P ¼ 0.012) and patient age (continuous P ¼ 0.039, 422 (median) P ¼ 0.028 and by decade P ¼ 0.023) negatively affected survival, whereas in a multivariate Cox regression, only normal/low gd T cells (P ¼ 0.0002) remained significant for poor survival. Patients with normal/ low gd had 6.7 (95% CI 2.4-18.1) times greater risk of death than those who had increased gd T cells (Table 3) .
GvHD
It is of interest that despite infusion of a higher T cell dose and recovery of gd T cells to a higher level, there was no increase in the incidence of acute GvHD in the study group (Figure 2 ).
Relapse
Five of 18 patients in the increased gd T cell group relapsed compared to 48 of 135 in the normal/low gd group (P-value ¼ 0.65). Relapsed patients with increased gd T cells were more likely to be salvaged (and hence the difference between risk of relapse and LFS). Three of five (60%) patients with increased gd T cells who relapsed after transplant were surviving at the time of the analysis (all received donor leukocyte infusion) compared to only one survivor out of 48 relapsed patients in the normal/low gd group.
Cause of death
Patients with normal/low numbers of gd T cells died from recurrent disease (n ¼ 49), graft failure (n ¼ 3), GvHD (n ¼ 12), infection (n ¼ 18), secondary malignancy (n ¼ 8) and other transplant-related toxicities (n ¼ 14). Patients with an increased gd T cell count died from relapse (n ¼ 2), chronic GvHD (n ¼ 1) and viral infection (n ¼ 1).
Discussion
Our data demonstrate a long-term survival advantage in a group of high-risk acute leukemia patients who recovered with increased number of circulating gd T cells following partially mismatched related HSCT, with no increased Long-term LFS with increased cd T cells post stem cell transplantation KT Godder et al incidence of acute GvHD, confirming and extending previously published preliminary findings. 29 These patients were four times more likely to survive disease-free compared to patients who recovered with normal or lower numbers of this specific T cell subset.
As activated gd T cells were shown to facilitate alloengraftment, 35, 36 we censored all patients before day þ 59 (the earliest gd T cell population recovery), thereby excluding patients who succumb to early transplant mortality or non-engraftment, and decreasing the likelihood of a selective bias. Given the small number of patients who recovered with increased gd T cells, there were limitations to a more extensive and conclusive analysis. Considering that patients were included if they developed increased gd T cells at any time in the first year post transplant, we may have selected patients who were fit for repeated studies and had more chance to develop a high gd T cells by virtue of their longer survival. To prevent such a selective bias, we performed a subset analysis including only those patients who survived beyond day þ 140 (the median day of increased gd T cells), and still proved survival advantage to patients with increased level of gd T cell subset. Additionally, median survival of low/normal gd patients was 193 days compared to median survival for the high gd patients of 140 days, further excluding the possibility of survival bias. Moreover, our study was strengthened by a patient cohort treated in the same institution, with standardized treatment protocols including a partial T cell-depleted marrow from a haploidentical donor, a uniform post transplant GvHD prophylaxis regimen (cyclosporine, steroids and anti-thymocyte globulin) and support care management. 30, 31, 33 Thereby, other potential confounders of transplant outcomes, such as, anti-infective, general practice care, graft manipulation for T cell depletion, and GvHD prophylaxis and treatment, were eliminated.
The low incidence of acute GvHD in patients recovering with increased circulating gd T cells is not surprising because these T cells do not recognize classical MHCassociated antigens and are not expected to initiate GvHD. Data from our laboratory and others indicate that gd T cells do not require MHC class II for their maturation 37 or proliferation in response to an allogeneic MHC disparity 38 and are not initiators of GvHD. 39 Moreover, Drobyski 40 showed that large doses of interleukin- 41 showed that although activated gd and naive ab T cells exacerbated GvHD when infused together, delaying the infusion of ab T cells by 2 weeks resulted in improved survival. These findings are consistent with Ellison, 42 who noted that gd T cells could be activated in the GvHD reaction but found no evidence that GvHD was initiated by gd T cells.
In human studies, Schilbach 43 and Lamb 38 found that gd T cells are not substantially activated in the in vitro allogeneic mixed lymphocyte culture. Several post BMT studies have shown transient increases in gd T cells [44] [45] [46] but have not associated this finding with GvHD, although Tsuji 47 found that gd T cells could be recruited to lesions and activated by CD4 þ ab T cells. Kawanishi 36 studied 273 recipients of T10B9 T cell-depleted bone marrow graft (62 from HLA-matched sibling donors, 54 PMRD and 157 unrelated donors) and showed that the gd T cell dose was not associated with the risk of acute or chronic GvHD.
Our next question was whether the improved LFS in our study was related to an anti-leukemic effect of gd T cells. Because of the small number of patients and the relatively rare event, it was difficult to show differences in risk of relapse between the increased and normal/low gd T cell groups. Nevertheless, other studies have suggested a gd T cell-mediated anti-leukemic effect. Using in vivo activated gd T cells (with IL-2 and pamidronate), Wilhelm et al 48 observed anti-leukemic responses in three of 10 high-risk patients. Laboratory studies from our group have shown that co-culture of donor-derived gd T cells with recipient ALL cells results in proliferation of predominantly Vd1 þ cells and a time-dependent lysis. This effect was not noted when gd T cells were incubated with third party mononuclear cells. 38, 43 The expanded gd T cell subtype in 490% of our survivors was predominately Vd1 þ . Although the biological implications of this finding are incompletely understood, previous studies suggest both a depletion of the Vd2 subset and activation and expansion of the Vd1 subset may be responsible for this. [49] [50] [51] [52] [53] [54] [55] [56] [57] Whether these findings are unique to T cell-depleted grafts is not clear because there are very few publications on immune reconstitution post HSCT that report on recovery of the gd T cell subpopulation. In general, studies on immune reconstitution post HSCT demonstrate no significant qualitative differences between recipients of T cell-depleted and recipients of unmodified grafts, although immune reconstitution is relatively delayed in the T celldepleted group. [58] [59] [60] Lamb 61 showed that a post BMT absolute increase in gd T cells was significantly associated with ab T cell depletion, as patients who received grafts that were T cell depleted with OKT3, a pan T cell monoclonal antibody, rarely showed an increase in gd T cells post BMT (P ¼ 0.05). However, there was no difference in survival between the two T cell depletion (TCD) regimens for patients who developed increased gd T cells. Whether an increased gd T cell represents a faster immune reconstitution and not a specific subset recovery is possible; however, in earlier studies, we have shown that the lymphocyte subsets recovery post PMRD HSCT follows a 'normal' recovery pattern.
Other than this report, only 2 small studies report on gd T cell recovery post transplant; in the first, the authors associated the increase in gd T cell with frequent serious infections, 44 whereas in the other with acute GvHD. 46 Our patients with increased gd T cell recovery did not suffer from frequent infections, including CMV reactivation, nor did they have an increased incidence of GvHD. Possible reasons for the differences between the studies may be related to different graft manipulation and GvHD prophylaxis.
Another interesting observation in our patients with increased gd T cells was the prolonged survival post HSCT relapse, as most patients were salvageable with post transplant therapy (mostly DLI). This is in contrast to patients with normal/low gd T cell counts who succumb shortly after relapse. This observation, although in a small group of patients, may be related to recommencement of the surveillance role of donor-originated gd T cells. 23 This report extends our previously published findings from a single institution showing an association between increased gd T cells and LFS in PMRD-BMT patients. In addition, we have summarized investigational laboratory findings that confirm the capability of gd T cells to recognize and kill leukemic cells. Taken together, adoptive cellular therapy with gd T cells may provide a reasonable approach to prevention of leukemic relapse in the immediate post transplant period, when the immune system is severely compromised, without additional risk of acute GvHD.
